Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News SCYNEXIS Inc SCYX

Healthcare
SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It develops antifungal platform fungerps, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a range of human fungal pathogens,... see more

Recent & Breaking News (NDAQ:SCYX)

Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018

PR Newswire June 6, 2018

SCYNEXIS Announces the Publication of Phase 1 Study Results for SCY-078 in The Journal of Clinical Pharmacology

PR Newswire June 6, 2018

SCYNEXIS to Present SCY-078 Data at ASM Microbe 2018

PR Newswire May 24, 2018

SCYNEXIS to Participate in a Panel at the 2018 BIO International Convention

PR Newswire May 23, 2018

SCYNEXIS Reports First Quarter 2018 Financial Results and Provides Company Update

PR Newswire May 8, 2018

SCYNEXIS's Oral SCY-078 Receives FDA QIDP and Fast Track Designations for the Treatment of VVC and Prevention of Recurrent VVC

PR Newswire May 1, 2018

SCYNEXIS Data Presentations at ECCMID 2018 Show SCY-078 Potent and Synergistic Antifungal Activity Against Aspergillus and Pneumocystis

PR Newswire April 23, 2018

Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

PR Newswire April 20, 2018

SCYNEXIS to Present SCY-078 Data at the 28th European Congress of Clinical Microbiology and Infectious Disease (ECCMID)

PR Newswire April 10, 2018

SCYNEXIS to Present at the 17th Annual Needham Healthcare Conference

PR Newswire March 21, 2018

SCYNEXIS Presents Data at Superbugs and Superdrugs 2018

PR Newswire March 20, 2018

SCYNEXIS to Present at the 30th Annual ROTH Conference

PR Newswire March 7, 2018

SCYNEXIS Announces Pricing of $30.0 Million Public Offering of Common Stock and Warrants

PR Newswire March 6, 2018

SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants

PR Newswire March 5, 2018

SCYNEXIS Presents New In Vivo Data Highlighting the Potential of SCY-078 Used in Combination for the Treatment of Aspergillus Infections at AAA 2018

PR Newswire February 1, 2018

SCYNEXIS to Participate in the Cantor Antibiotics Summit

PR Newswire January 11, 2018

SCYNEXIS Provides Corporate and SCY-078 Pipeline Update

PR Newswire January 4, 2018

SCYNEXIS to Participate in Upcoming Investor Conferences

PR Newswire November 28, 2017

SCYNEXIS to Present at the 29th Annual Piper Jaffray Healthcare Conference

PR Newswire November 22, 2017

SCYNEXIS Appoints Scott Sukenick as General Counsel

PR Newswire November 16, 2017